Tired of hiding your depression? If your current antidepressant medication(s) is/are not adequately improving symptoms of your majored pressive disorder (MDD), you may be eligible for the AMPA-VEGA 1 STUDY. This study is researching an investigational medication to see if it is safe and whether it improves symptoms of MDD when taken with your current antidepressant medication(s).
About this study
The AMPA-VEGA 1 STUDY is part of the AMPA PROGRAM and is researching an investigational medication to see if it may delay relapse of MDD symptoms when taken alongside current antidepressant medications.
The investigational medication being evaluated in this study is an oral tablet that will be taken once daily. A placebo will be used to provide researchers with a baseline that they can compare the investigational medication to.
To keep the research results as accurate as possible, participants, study doctors and the study research teams will not know if you are receiving the investigational medication or placebo. Participants who receive the placebo will get the same care as participants who receive the investigational medication.
Anticipated enrolment close date: October 2026
Who can take part
You may be eligible to participate if you:
- are at least 18 years old
- have a primary diagnosis of MDD
- are currently receiving at least 1 antidepressant medication
- have had inadequate response(s) to up to 5 oral antidepressant medications
You may not be eligible to participate if you:
- are pregnant, breastfeeding or planning to become pregnant during the study
Other eligibility criteria may apply.
What's involved for you
Participation in this study is variable in length. It is expected to last at least 5 months and may exceed 24 months. Participants can anticipate monthly visits, with a few weekly visits. The number of visits is related to the length of time you are in the study.
Participants in this study will:
- receive the investigational medication for 16 weeks
- be assigned at random to either continue receiving the investigational medication or begin receiving the placebo (the assigned study treatment)
- receive the assigned study treatment and study-related procedures at no cost
- be reimbursed for applicable travel costs and inconveniences while in the study, depending on your region
- continue taking your current antidepressant while also taking the assigned study treatment daily
- receive support from your study doctor and site staff, who will check on your health while you are in the study
- have the option to be enrolled in other studies once you have completed this study
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by an Australian registered and certified HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2025). This statement protects the interests of people who agree to participate in human research studies.